CLINICAL TRIALS PROFILE FOR IVACAFTOR; LUMACAFTOR

All Clinical Trials for IVACAFTOR; LUMACAFTOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01225211 ↗	Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation	Completed	Vertex Pharmaceuticals Incorporated	Phase 2	2010-10-01	The purpose of this study is to evaluate of the safety, efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) effects of lumacaftor (VX-809) alone and when coadministered with ivacaftor (VX-770) in participants with cystic fibrosis, homozygous or heterozygous for the F508del-CFTR mutation.
NCT01768663 ↗	A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2013-01-01	The purpose of this study is to examine the drug-drug interaction effects of ciprofloxacin, itraconazole, and rifampin on the pharmacokinetics of lumacaftor in combination with ivacaftor as well as to evaluate the potential effects of lumacaftor in combination with ivacaftor on lung function.
NCT01807923 ↗	A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2013-05-01	The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.
NCT01807949 ↗	A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2013-04-01	The primary objective of the study was to evaluate the efficacy of lumacaftor in combination with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.
NCT01888393 ↗	Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects	Completed	Vertex Pharmaceuticals Incorporated	Phase 1	2013-06-01	This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of lumacaftor in combination with ivacaftor in subjects with moderate hepatic impairment.
NCT01897233 ↗	Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2013-07-01	This is a Phase 3, 2-part (Part A and Part B), open-label, multicenter study to evaluate the pharmacokinetics, safety, and tolerability of lumacaftor in combination with ivacaftor in subjects with cystic fibrosis aged 6 to 11 years who have the F508del-mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Clinical Trial Conditions for IVACAFTOR; LUMACAFTOR

Condition Name

Condition Name for IVACAFTOR; LUMACAFTOR
Intervention	Trials
Cystic Fibrosis	30
Healthy Volunteer	2
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation	2
Diabetes	2

Condition MeSH

Condition MeSH for IVACAFTOR; LUMACAFTOR
Intervention	Trials
Cystic Fibrosis	33
Fibrosis	27
Lung Diseases	2
Liver Diseases	1

Clinical Trial Locations for IVACAFTOR; LUMACAFTOR

Trials by Country

Trials by Country for IVACAFTOR; LUMACAFTOR
Location	Trials
United States	371
Canada	32
France	23
Germany	19
United Kingdom	19

Trials by US State

Trials by US State for IVACAFTOR; LUMACAFTOR
Location	Trials
Missouri	16
Colorado	16
Massachusetts	15
California	15
Ohio	15

Clinical Trial Progress for IVACAFTOR; LUMACAFTOR

Clinical Trial Phase

Clinical Trial Phase for IVACAFTOR; LUMACAFTOR
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	12
Phase 2	5

Clinical Trial Status

Clinical Trial Status for IVACAFTOR; LUMACAFTOR
Clinical Trial Phase	Trials
Completed	23
Recruiting	5
Terminated	3

Clinical Trial Sponsors for IVACAFTOR; LUMACAFTOR

Sponsor Name

Sponsor Name for IVACAFTOR; LUMACAFTOR
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	21
Children's Hospital Medical Center, Cincinnati	2
Nivalis Therapeutics, Inc.	2

Sponsor Type

Sponsor Type for IVACAFTOR; LUMACAFTOR
Sponsor	Trials
Industry	26
Other	15
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Ivacaftor and Lumacaftor

Last updated: October 28, 2025

---

Introduction

Ivacaftor and Lumacaftor are key pharmaceuticals targeting cystic fibrosis (CF), a genetic disorder that causes severe respiratory and digestive problems. Approved by the FDA in 2012, Ivacaftor was the first drug to target the underlying cause of CF in specific mutations. Lumacaftor, approved in combination with Ivacaftor (marketed as Orkambi), enhances CFTR protein function for individuals with the F508del mutation, the most common CF mutation. These drugs represent significant advancements in personalized medicine for CF. This report synthesizes latest clinical trial updates, market dynamics, and future outlooks for Ivacaftor and Lumacaftor.

---

Clinical Trials Update

Ivacaftor

Since its initial approval, Ivacaftor's development pipeline has focused on expanding indications beyond the G551D mutation, which it originally targeted. Recent high-profile trials include:

• Pediatric Expansions: The phase 3 FLUENT trial (2021) demonstrated safety and efficacy of Ivacaftor in children aged 2-5 with G551D mutations, leading to expanded pediatric labeling.
• New Mutation Targets: Trials are ongoing for rarer CF mutations; for example, a phase 3 study evaluates Ivacaftor efficacy in patients with R117H mutation, with preliminary results indicating positive safety profiles but variable efficacy across mutation types [1].

Lumacaftor

Lumacaftor, combined with Ivacaftor, continues to be evaluated through post-approval studies and new combination trials:

• Combination Optimizations: The phase 3 ENVISION trial (2022) assessed Lumacaftor/Ivacaftor in patients with F508del homozygous mutations, focusing on long-term respiratory outcomes. Results affirm sustained lung function improvements and manageable safety profiles [2].

• Next-Generation Modulators: New CFTR modulators, including Tezacaftor and Elexacaftor (as part of Trikafta), are supplanting Lumacaftor/Ivacaftor due to superior efficacy. However, ongoing trials evaluate the potential for Lumacaftor to be used in combination therapies for mutation-specific indications.

Regulatory and Safety Considerations

Both drugs continue to undergo pharmacovigilance reviews. Recent data underscore rare but serious hepatic adverse events linked with CFTR modulators, prompting further investigation but not leading to significant regulatory restrictions.

---

Market Analysis

Market Size and Key Drivers

The global cystic fibrosis drugs market, valued at USD 4.2 billion in 2022, is projected to grow at a CAGR of approximately 8.5% through 2030, driven primarily by:

• Expanding Patient Population: Advances in diagnostics and newborn screening have increased identified cases, enabling earlier intervention.
• Enhanced Treatment Options: The shift toward mutation-specific CFTR modulators like Ivacaftor and Lumacaftor broadens eligibility.

Key Market Players

• Vertex Pharmaceuticals: Dominates with the Ivacaftor ecosystem, including Trikafta (Elexacaftor/Tezacaftor/Ivacaftor), which has captured significant market share.
• AbbVie and Moderna: Focused on developing next-generation CFTR modulators and gene therapy, potentially disrupting current modalities.

Pricing and Reimbursement

Ivacaftor's annual list price exceeds USD 300,000 per patient. Despite high costs, insurance coverage is robust due to the high unmet medical need. Market access remains a challenge in lower-income regions, but efforts redirect toward global expansion and biosimilars.

---

Future Market Projections

• Shift Toward Next-Generation Modulators: The advent of Trikafta and other triple-combination therapies will likely diminish Lumacaftor/Ivacaftor's market share over the next five years.
• Geographical Expansion: Emerging markets in Asia and Latin America present opportunities due to increasing awareness and diagnostic capabilities.
• Pipeline Innovations: Gene editing and mRNA-based therapies are in early-stage development but could revolutionize CF treatment by addressing the root genetic cause more comprehensively.

The sustained demand for CF modulators, combined with continued innovation, supports a forecast where the CFTR modulator market reaches USD 8.5 billion by 2030, with Ivacaftor and Lumacaftor maintaining niche roles until replaced by more effective therapies.

---

Regulatory and Commercial Outlook

Regulatory agencies worldwide are evaluating the efficacy and safety of existing and pipeline CF drugs, with some countries approving expanded indications for Ivacaftor. Commercial strategies are shifting toward personalized approaches, including genetic testing to ensure optimal therapy selection.

---

Key Takeaways

• Clinical development for Ivacaftor is focusing on rare mutations and pediatric populations; Lumacaftor's role is diminishing with emerging therapies.
• The market for CFTR modulators is robust, driven by increased diagnosis and pipeline innovations, but faces pricing and access challenges.
• Next-generation therapies such as Trikafta are expected to eclipse Lumacaftor/Ivacaftor, with a projected market expansion to USD 8.5 billion by 2030.
• Global expansion remains a priority, especially in underserved markets, to maximize therapeutic access and growth.
• Regulatory trends favor combination therapies with improved efficacy and safety profiles, signaling a transformative period for CF treatment paradigms.

---

FAQs

1. What is the primary difference between Ivacaftor and Lumacaftor?
Ivacaftor potentiates CFTR protein function at the cell surface, whereas Lumacaftor acts as a corrector, assisting misfolded CFTR proteins to reach the cell surface. Their combination enhances overall CFTR activity in certain mutations.

2. Why is Lumacaftor being phased out in favor of newer therapies?
Emerging triple-combination drugs like Trikafta demonstrate superior efficacy, safety, and broader mutation coverage, reducing Lumacaftor’s clinical utility.

3. Are Ivacaftor and Lumacaftor effective for all CF mutations?
No. Ivacaftor is primarily effective for gating mutations like G551D. Lumacaftor is used mainly in homozygous F508del mutations. Mutation-specific therapies limit broad applicability.

4. What challenges does the market face for these drugs?
High costs, limited access in low-income regions, and competition from next-generation therapies threaten the current market dominance of Ivacaftor and Lumacaftor.

5. What is the outlook for the CFTR modulator market?
The market is poised for growth, driven by pipeline innovations, expanded indications, and improved diagnostic strategies, with a move towards more effective and personalized therapies.

---

References

[1] Cystic Fibrosis Foundation. (2022). "Ivacaftor Expansion Trials."
[2] Vertex Pharmaceuticals. (2022). "ENVISION trial results on Lumacaftor/Ivacaftor."